Our first public demo is now live. Researchers and institutions can explore UndosaTech's federated analysis interface, see how the governance layer works, and experience the no-code AI tools firsthand. Sign in with your institutional or Google account.
Open Demo →The FDA contacted over 2,200 clinical trial sponsors about unreported results — 29.6% of applicable trials have never submitted required data. We examine what this signals for secondary use frameworks.
Read source →The foundational 2009 Lancet paper that estimated 85% of biomedical research investment is avoidably wasted through flawed design, non-publication, and poor reporting — the core problem UndosaTech addresses.
Read paper →Rieke et al. in npj Digital Medicine lay out why federated learning is the most promising architecture for enabling cross-institutional biomedical AI — without compromising patient privacy or institutional governance.
Read paper →A Phase III Alzheimer's trial averages $370M and takes up to 8 years — with a 95% failure rate among drug candidates. Better cross-institutional data access is a direct lever on this crisis.
Read source →Foley & Lardner's legal analysis of the FDA's enforcement push — what it means in practice for sponsors, the penalties at stake, and what the shift toward data transparency means for research infrastructure.
Read analysis →PLOS Medicine analysis of how publication bias and access barriers compound research waste — estimating over $100B lost annually. The case for open, governed secondary use of research data.
Read paper →Every statistic on this site is sourced. Click through to read the original papers and reports.